CLAIM #27325 · GILD (GILD) · 2025Q3 earnings call · Oct 30, 2025 · due Dec 31, 2025
“we remain on track to provide updates for our Phase III ARTISTRY-1 and ARTISTRY-2 trials for BIC/LEN and for our pivotal Phase II iMMagine-1 trial for anito-cel in the fourth quarter.”
Dietmar Berger · Chief Medical Officer
PENDING
graded after results covering Dec 31, 2025 are reported
Verify independently
SEC filings for GILD ↗ · Claim quote is verbatim from the 2025Q3 earnings call.